Epithelioid hemangioendotheliomas အသည်းကင်ဆာတမျိုး

မင်္ဂလာပါ ဆရာ ကျွန်တော့် အစ်မ က အသက် ၃၆ နှစ်ပါ  hemangioendothelioma cancer ဖြစ်နေပြီး အကြိတ်က အသည်းမှာ ဖြစ်နေပါတယ်ဆရာ

ဘာသာမပြန်အားသေးပါ။ ကင်ဆာအထူးကုဆရာဝန်နဲ့ ကုသရပါမယ်။ ဖေါစ်ဘွတ်ကနေ ဟိုပြောဒီပြောတွေကို လိုက်နာရန် ရှောင်ရန် မလိုပါ။

Epithelioid hemangioendotheliomas (EH) are vascular tumors that may affect the liver, lungs, mediastinum, and multiple other sites. However, the most commonly involved organ is the liver[1]. Primary epithelioid hemangioendotheliomas of the liver (EHL) are rare tumors with an incidence rate of less than 0.1 per 100000 population. Due to the low incidence rate, not a lot is understood regarding the pathogenesis of this tumor. However, it has been shown that EHL have a predilection for females, with a female-to-male ratio of 3:2, and affects the right lobe of the liver more than the left lobe. These tumors may be asymptomatic (24.8%), or symptomatic, with right upper quadrant pain being the most common presenting symptom (48.6%)[2]. The lungs, regional lymph nodes, peritoneum, bone, spleen, and diaphragm are the most common sites of extrahepatic involvement[2,3].

Epithelioid hemangioendothelioma, or EHE, is a rare cancer that grows from the cells that make up the blood vessels. This cancer can occur anywhere in the body with the most common sites being the liver, lungs, and bone.

Epithelioid hemangioendothelioma (EHE) is a rare malignant tumor with a vascular origin, and it primarily occurs in the liver. The incidence rate for hepatic EHE (HEHE) is approximately 1–2 per million individuals, while the mortality rate is between 40 and 65% [1, 2].

Transcatheter arterial chemoembolization also has been used to treat HEHE within the liver[53]. Surgical resection is considered to be the best treatment, especially for single small HEHE.

Based on the SEER database, our results demonstrated that the overall 1- and 5-year survival rates to be 70.8% and 55.6%, respectively.

ဒေါက်တာတင့်ဆွေ